Patents Assigned to Lay Line Genomics S.p.A.
  • METHOD FOR THE HUMANIZATION OF ANTIBODIES AND HUMANIZED ANTIBODIES THEREBY OBTAINED
    Publication number: 20140316113
    Abstract: Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.
    Type: Application
    Filed: March 17, 2014
    Publication date: October 23, 2014
    Applicants: Lay Line Genomics S.p.A., Scuola Internazionale Superiore di Studi Avanzati
    Inventors: Antonino Cattaneo, Doriano Lamba, Sonia Covaceuszach
  • Method for the potentiation of opioid analgesics effects on pain
    Patent number: 8715666
    Abstract: According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: May 6, 2014
    Assignee: Lay Line Genomics S.p.A.
    Inventors: Flaminia Pavone, Sara Marinelli, Antonio Cattaneo, Gabriele Ugolini
  • Analgesic treatment with prolonged effect
    Patent number: 8691221
    Abstract: Use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA, in particular capable of blocking the biological activity of TrkA, for the preparation of a medicament for treating and/or preventing chronic pain.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: April 8, 2014
    Assignee: Lay Line Genomics S.p.A.
    Inventors: Flaminia Pavone, Sara Marinelli, Antonio Cattaneo, Gabriele Ugolini
  • Monoclonal antibodies binding to TrkA and acting as NGF-antagonist molecules and their use for treating pain induced by NGF
    Patent number: 8486401
    Abstract: Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognise the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: July 16, 2013
    Assignee: Lay Line Genomics S.p.A.
    Inventor: Michal M. Novak
  • Method for the potentiation of opioid analgesics effects on pain
    Patent number: 7988966
    Abstract: According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: August 2, 2011
    Assignee: Lay Line Genomics S.p.A.
    Inventors: Flaminia Pavone, Sara Marinelli, Antonino Cattaneo, Gabriele Ugolini
  • Monoclonal antibodies and antigen binding fragments thereof capable of binding TrkA and inhibiting the functional activation of TrkA
    Patent number: 7601352
    Abstract: Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognize the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: October 13, 2009
    Assignee: Lay Line Genomics S.p.A.
    Inventor: Michal M. Novak
  • 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method
    Patent number: 7589219
    Abstract: 2,5-bis-diamine-[1,4]benzoquinonic derivatives, having a general formula (I) have proved useful for the treatment of Alzheimer's disease; a method for preparing them and intermediates used in said method are also described.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: September 15, 2009
    Assignees: Alma Mater Studiorum-Universita' Di Bologna, Lay Line Genomics S.p.A.
    Inventors: Vincenza Andrisano, Manuela Bartolini, Maria Laura Bolognesi, Andrea Cavalli, Carlo Melchiorre, Maurizio Recanatini
  • Method for the potentiation of opioid analgesics effects on pain
    Publication number: 20090123464
    Abstract: According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.
    Type: Application
    Filed: June 23, 2006
    Publication date: May 14, 2009
    Applicant: Lay Line Genomics S.p.A.
    Inventors: Flaminia Pavone, Sara Marinelli, Antonino Cattaneo, Gabriele Ugolini